Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

Luciano J. Costa, Parameswaran Hari, Jesus G. Berdeja, Valerio De Stefano, Francesca Gay, Becky Hooper, Meaghan Bartlett, Anja Haltner, Emily Rosta, Shaji Kumar, Thomas Martin, Maria Victoria Mateos, Philippe Moreau, Saad Z. Usmani, Yunsi Olyslager, Jordan M. Schecter, Tito Roccia, Ashraf Garrett, Sam Lee, Tonia NesheiwatLida Pacaud, Changwei Zhou, Imtiaz A. Samjoo, Yi Lin, Joris Diels, Satish Valluri, Katja Weisel

Research output: Contribution to journalArticlepeer-review


Objective: In the absence of head-to-head trials, indirect treatment comparisons (ITCs) between ciltacabtagene autoleucel (cilta-cel; in CARTITUDE-1) and treatments used in real-world clinical practice (physician’s choice of treatment [PCT]), were previously conducted. We conducted multiple meta-analyses using available ITC data to consolidate the effectiveness of cilta-cel versus PCT for patients with triple-class exposed relapsed or refractory multiple myeloma (RRMM). Methods: Five ITCs were assessed for similarity to ensure robust comparisons using meta-analysis. Effectiveness outcomes were overall survival (OS), progression-free survival (PFS), time to next treatment (TTNT), and overall response rate (ORR). A robust variance estimator was used to account for the use of CARTITUDE-1 in each pairwise ITC. Analyses were conducted in both treated and enrolled populations of CARTITUDE-1. Results: Four ITCs were combined for evaluation of OS. Results were statistically significantly in favor of cilta-cel versus PCT in treated patients (hazard ratio [HR]: 0.24, 95% confidence interval [CI]: 0.22–0.26). Three ITCs were combined for evaluation of PFS and TTNT. Cilta-cel reduced the risk of progression and receiving a subsequent treatment by 80% (HR: 0.20 [95% CI: 0.06, 0.70]) and 83% (HR: 0.17 [95% CI: 0.12, 0.26]), respectively. Three ITCs were combined for evaluation of ORR. Cilta-cel increased the odds of achieving an overall response by 86-times versus PCT in treated patients. Findings were consistent in the enrolled populations and across sensitivity analyses. Conclusions: Evaluating multiple indirect comparisons, cilta-cel demonstrated a significantly superior advantage over PCT, highlighting its effectiveness as a therapy in patients with triple-class exposed RRMM.

Original languageEnglish (US)
Pages (from-to)1759-1767
Number of pages9
JournalCurrent Medical Research and Opinion
Issue number10
StatePublished - 2022


  • CAR-T
  • Relapsed or refractory multiple myeloma
  • ciltacabtagene autoleucel
  • meta-analysis
  • triple-class exposed

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma'. Together they form a unique fingerprint.

Cite this